Skip to main content
. Author manuscript; available in PMC: 2013 May 30.
Published in final edited form as: J Med Toxicol. 2011 Jun;7(2):133–138. doi: 10.1007/s13181-011-0149-3

Fig. 2.

Fig. 2

a Good adherence to HAART regimen, b HIV simulation with one medication (atazanavir) in suboptimal concentration, c simulation of HIV status with one medication in minimal concentration, d simulation of HIV with poor adherence, e simulation of HIV state after prolonged good adherence, f simulated HIV state after prolonged poor adherence